KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Current Liabilities (2016 - 2025)

NovoCure (NVCR) has disclosed Total Current Liabilities for 12 consecutive years, with $223.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 70.49% to $223.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $223.2 million through Dec 2025, down 70.49% year-over-year, with the annual reading at $223.2 million for FY2025, 70.49% down from the prior year.
  • Total Current Liabilities hit $223.2 million in Q4 2025 for NovoCure, down from $776.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $776.0 million in Q3 2025 to a low of $110.5 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $300.3 million across 5 years, with a median of $158.0 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: surged 367.67% in 2024 and later crashed 70.49% in 2025.
  • Year by year, Total Current Liabilities stood at $142.6 million in 2021, then grew by 11.34% to $158.8 million in 2022, then rose by 12.81% to $179.1 million in 2023, then soared by 322.3% to $756.4 million in 2024, then plummeted by 70.49% to $223.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for NVCR at $223.2 million in Q4 2025, $776.0 million in Q3 2025, and $749.6 million in Q2 2025.